Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2025 02:30 ET | Source: Alvotech

Mikil umframeftirspurn alþjóðlegra fjárfesta í útboði Alvotech á breytanlegra skuldabréfum að fjárhæð 108 milljónir dollara

REYKJAVÍK (17. DESEMBER 2025) - Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að fyrirtækið hefði selt breytanleg skuldabréf að fjárhæð 108 milljónir bandaríkjadala til hóps um 20 alþjóðlegra...
December 17, 2025 02:30 ET | Source: Alvotech

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH...
December 16, 2025 11:48 ET | Source: Alvotech

Alvotech býður út breytanleg skuldabréf að fjárhæð 100 milljónir bandaríkjadala til að viðhalda fjárfestingu í lyfjaþróun, framleiðslu, markaðssetningu og styrkja lausafjárstöðu, staðfestir afkomuspá 2025 og birtir afkomuspá ársins 2026

REYKJAVÍK - (16. DESEMBER 2025) Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að fyrirtækið efni til útboðs á breytanlegum skuldabréfum að fjárhæð 100 milljónir dollara með gjalddaga á árinu 2030....
December 16, 2025 11:48 ET | Source: Alvotech

Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH...
December 10, 2025 07:30 ET | Source: Medicenna Therapeutics Corp.

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case...
December 09, 2025 17:04 ET | Source: Medicenna Therapeutics Corp.

Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data

TORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
November 06, 2025 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto...
November 04, 2025 16:01 ET | Source: Alvotech

Alvotech kynnir afkomu fyrstu níu mánaða ársins og ræðir nýjustu áfanga í rekstri félagsins þann 13. nóvember nk.

Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrstu níu mánaða ársins 2025 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 12. nóvember nk. Fundur til kynningar á uppgjörinu verður...
November 04, 2025 16:01 ET | Source: Alvotech

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

REYKJAVIK, ICELAND (November 4, 2025) – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today...
October 23, 2025 17:12 ET | Source: Medicenna Therapeutics Corp.

Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the...